Anti-tumour necrosis factor therapy in seronegative spondyloarthritis

被引：0

作者：

Swales, C ^{[1
]}

Bowness, P ^{[1
]}

机构：

[1] Nuffield Orthopaed Ctr NHS Trust, Nuffield Orthopaed Ctr, Oxford OX3 7LD, England

来源：

CLINICAL MEDICINE | 2005年 / 5卷 / 03期

关键词：

D O I：

10.7861/clinmedicine.5-3-219

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Over 50% of ankylosing spondylitis patients treated with anti-tumour necrosis factor show a 50% improvement Infliximab, etanercept (and probably adalimumab) are equally effective Stable responses are maintained for two years If treatment is discontinued, almost all patients relapse Retreatment is probably as effective as initial treatment Pre-test screening for tuberculosis is essential The overall risk to benefit ratio is favourable.

引用

页码：219 / 222

页数：4

共 50 条

[41] Pseudo-mycosis fungoides induced by anti-tumour necrosis factor therapy
Chan, S-L.
Chan, J. J.
Wood, B.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2016, 57 : 6 - 6
[42] Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-α therapy
Roux, C. H.
Brocq, O.
Breuil, V.
Albert, C.
Euller-Ziegler, L.
RHEUMATOLOGY, 2007, 46 (04) : 695 - 698
[43] Long-term outcome of anti-tumour necrosis factor alpha blockade in the treatment of juvenile spondyloarthritis
Hugle, B.
Burgos-Vargas, R.
Inman, R. D.
O'Shea, F.
Laxer, R. M.
Stimec, J.
Whitney-Mahoney, K.
Duvnjak, M.
Anderson, M.
Tse, S. M. L.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (03) : 424 - 431
[44] THE DRUG SURVIVAL OF ANTI-TUMOUR NECROSIS FACTOR (TNF) TREATMENT IN A UK COHORT OF AXIAL SPONDYLOARTHRITIS PATIENTS
Yahya, F.
Cavill, C.
Berry-Jenkins, J.
Bond, D.
Boyle, C.
Sengupta, R.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 810 - 811
[45] Reporting the response to anti-tumour necrosis factor treatment
Volc, S.
Ghoreschi, K.
BRITISH JOURNAL OF DERMATOLOGY, 2016, 175 (05) : 867 - 868
[46] ANKYLOSING SPONDYLITIS: ANTI-TUMOUR NECROSIS FACTOR AND BEYOND
Sengupta, Raj
RHEUMATOLOGY, 2017, 56 : 10 - 10
[47] The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor
Harrold, Leslie R.
Reed, George W.
Kremer, Joel M.
Curtis, Jeffrey R.
Solomon, Daniel H.
Hochberg, Marc C.
Greenberg, Jeffrey D.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (02) : 430 - 436
[48] The inadequate anti-tumour necrosis factor (anti-TNF) therapy in patients with ankylosing spondylitis
Borman, Pinar
Ayhan, Figen
Ceceli, Esma
RHEUMATOLOGY INTERNATIONAL, 2010, 30 (12) : 1689 - 1690
[49] The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis
Barkham, N
Kong, KO
Tennant, A
Fraser, A
Hensor, E
Keenan, AM
Emery, P
RHEUMATOLOGY, 2005, 44 (10) : 1277 - 1281
[50] The inadequate anti-tumour necrosis factor (anti-TNF) therapy in patients with ankylosing spondylitis
Pinar Borman
Figen Ayhan
Esma Ceceli
Rheumatology International, 2010, 30 : 1689 - 1690

← 1 2 3 4 5 →